Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients

Human Mutation

Volumn 36, Issue 11, 2015, Pages 1088-1099

  Ronowicz, Anna ^a   Janaszak Jasiecka, Anna ^a   Skokowski, Jarosław ^a   Madanecki, Piotr ^a   Bartoszewski, Rafal ^a   Bałut, Magdalena ^a   Seroczyńska, Barbara ^a   Kochan, Kinga ^a   Bogdan, Adam ^a   Butkus, Małgorzata ^a   Peksa, Rafał ^a   Ratajska, Magdalena ^a   Kuźniacka, Alina ^a   Wasag, Bartosz ^a   Gucwa, Magdalena ^a   Krzyzanowski, Maciej ^a   Jaśkiewicz, Janusz ^a   Jankowski, Zbigniew ^a   Forsberg, Lars ^b   Ochocka, J Renata ^a   Limon, Janusz ^a   Crowley, Michael R ^c   Buckley, Patrick G ^d   Messiaen, Ludwine ^e   Dumanski, Jan P ^b   Piotrowski, Arkadiusz ^a   more..

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BEAUMONT HOSPITAL   (Ireland)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; CNA; CNV; Driver mutations; Genome stability; Rearrangement; Somatic mosaicism

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; NCOR1 PROTEIN; NUCLEAR RECEPTOR COREPRESSOR; PALB2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALLELE; ALLELIC IMBALANCE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CELL COUNT; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHROMATIN STRUCTURE; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA BINDING; FEMALE; FRAMESHIFT MUTATION; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMIC INSTABILITY; HETEROZYGOTE; HOMOLOGOUS RECOMBINATION; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LYMPH NODE METASTASIS; MISSENSE MUTATION; MOSAICISM; NONSENSE MUTATION; NUCLEAR LOCALIZATION SIGNAL; PATHOGENICITY; POINT MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SOMATIC MUTATION; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COPY NUMBER VARIATION; DNA MUTATIONAL ANALYSIS; GENE LOCUS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; REPRODUCIBILITY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; TUMOR BURDEN;

EID: 84944179656     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22845     Document Type: Article

References (108)

1. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, Morrison J, Maranian M, Pooley KA, Luben R, Eccles D, Evans DG, et al. 2009. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41:585-590.
2. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, et al. 2010. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42:885-892.
3. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, et al. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
4. Berger AH, Pandolfi PP. 2011. Haplo-insufficiency: a driving force in cancer. J Pathol 223:137-146.
5. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, Wells CE, Kaiser JF, et al. 2010. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18:436-447.
6. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, et al. 2013. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45:371-384, 384e1-2.
7. Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Pamula-Pilat J, Tecza K, Pekala W, et al. 2011. Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 52:325-330.
8. Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S, Diaz de Stahl T, Menzel U, Sandgren J, von Tell D, Poplawski A, Crowley M, Crasto C, et al. 2008. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 82:763-771.
9. Buysse K, Delle Chiaie B, Van Coster R, Loeys B, De Paepe A, Mortier G, Speleman F, Menten B. 2009. Challenges for CNV interpretation in clinical molecular karyotyping: lessons learned from a 1001 sample experience. Eur J Med Genet 52:398-403.
10. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. 2008. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8:187-198.
11. Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR. 2004. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet 149:38-43.
12. CGAN-consortium. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
13. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. 1996. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 271:32863-32868.
14. Choi DH, Lee MH, Haffty BG. 2006. Double heterozygotes for non-Caucasian families with mutations in BRCA-1 and BRCA-2 genes. Breast J 12:216-220.
15. Clarke CL, Sandle J, Jones AA, Sofronis A, Patani NR, Lakhani SR. 2006. Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br J Cancer 95:515-519.
16. Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington MK. 2012. AJCC Cancer Staging Atlas: A Companion to the 7th Editions of the AJCC Cancer Staging Manual and Handbook. New York: Springer. 637 p.
17. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, et al. 2013. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9:e1003212.
18. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, et al. 2012. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486:346-352.
19. Dawson SJ, Rueda OM, Aparicio S, Caldas C. 2013. A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32:617-628.
20. Dey BR, Furlanetto RW, Nissley SP. 1998. Cloning of human p55 gamma, a regulatory subunit of phosphatidylinositol 3-kinase, by a yeast two-hybrid library screen with the insulin-like growth factor-I receptor. Gene 209:175-183.
21. Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, et al. 2013. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov 3:399-405.
22. Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, et al. 2010. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol 17:1255-1259.
23. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, et al. 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087-1093.
24. Ellsworth RE, Ellsworth DL, Weyandt JD, Fantacone-Campbell JL, Deyarmin B, Hooke JA, Shriver CD. 2010. Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression. Ann Surg Oncol 17:1688-1694.
25. Euhus DM, Cler L, Shivapurkar N, Milchgrub S, Peters GN, Leitch AM, Heda S, Gazdar AF. 2002. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst 94:858-860.
26. Ferrarini A, Auteri-Kaczmarek A, Pica A, Boesch N, Heinimann K, Schafer SC, Vesnaver-Megalo S, Cina V, Beckmann JS, Monnerat C. 2011. Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Fam Cancer 10:187-192.
27. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, Coupland B, Broderick P, et al. 2011. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103:425-435.
28. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, Diaz de Stahl T, Zaghlool A, Giedraitis V, Lannfelt L, Score J, et al. 2014. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet 46:624-628.
29. Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Ronowicz A, Wineinger NE, Tiwari HK, Boomsma D, Westerman MP, Harris JR, et al. 2012. Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet 90:217-228.
30. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, Betts JA, Carroll T, et al. 2013. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet 92:489-503.
31. Friedman E, Bar-Sade Bruchim R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, Peretz T, Lerer I, et al. 1998. Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224-1227.
32. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, et al. 2013. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45:392-398, 398e1-2.
33. Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, et al. 2013. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 9:e1003173.
34. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J, Wang Q, Humphreys MK, Luccarini C, Baynes C, Conroy D, et al. 2012. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44:312-318.
35. Gilissen C, Hoischen A, Brunner HG, Veltman JA. 2012. Disease gene identification strategies for exome sequencing. Eur J Hum Genet 20:490-497.
36. Goldstein DB, Allen A, Keebler J, Margulies EH, Petrou S, Petrovski S, Sunyaev S. 2013. Sequencing studies in human genetics: design and interpretation. Nat Rev Genet 14:460-470.
37. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr., Kastrinakis NG, Levy B, Kletsas D, Yoneta A, et al. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913.
38. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. 2001. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092-4097.
39. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, et al. 2011. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 43:1210-1214.
40. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. 1997. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 16:298-302.
41. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, Sinilnikova O, Tihomirova L, Lubinski J, Gronwald J, Gorski B, Hansen T, et al. 2011. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 19:300-306.
42. Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, et al. 2012. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat 134:1229-1239.
43. Holliday C, Rummel S, Hooke JA, Shriver CD, Ellsworth DL, Ellsworth RE. 2009. Genomic instability in the breast microenvironment? A critical evaluation of the evidence. Expert Rev Mol Diagn 9:667-678.
44. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
45. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, et al. 2007. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870-874.
46. Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, Hutchinson A, Deng X, Liu C, Horner MJ, Cullen M, Epstein CG, et al. 2012. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44:651-658.
47. Jensen RB, Carreira A, Kowalczykowski SC. 2010. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467:678-683.
48. Karchin R, Agarwal M, Sali A, Couch F, Beattie MS. 2008. Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. Cancer Inform 6:203-216.
49. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
50. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. 2014. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46:310-315.
51. Klijn C, Bot J, Adams DJ, Reinders M, Wessels L, Jonkers J. 2010. Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach. PLoS Comput Biol 6:e1000631.
52. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, et al. 2011. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci USA 108:17773-17778.
53. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. 2010. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 4:255-266.
54. Larson PS, de las Morenas A, Cerda SR, Bennett SR, Cupples LA, Rosenberg CL. 2006. Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. J Pathol 209:307-316.
55. Larson PS, Schlechter BL, de las Morenas A, Garber JE, Cupples LA, Rosenberg CL. 2005. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 23:8613-8619.
56. Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, Ling H, Hetrick KN, Pugh EW, Amos C, Wei Q, Wang LE, et al. 2012. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 44:642-650.
57. Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G. 2011. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol 22:964-966.
58. Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, et al. 2005. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42:e20.
59. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760.
60. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J. 2007. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104:12111-12116.
61. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. 1997. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11:1226-12241.
62. Meng ZH, Ben Y, Li Z, Chew K, Ljung BM, Lagios MD, Dairkee SH. 2004. Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization. Genes Chromosomes Cancer 41:214-222.
63. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. 2011. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41.
64. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, et al. 2013. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45:353-361, 361e1-2.
65. Mottis A, Mouchiroud L, Auwerx J. 2013. Emerging roles of the corepressors NCoR1 and SMRT in homeostasis. Genes Dev 27:819-835.
66. Nakao K, Oikawa M, Arai J, Mussazhanova Z, Kondo H, Shichijo K, Nakashima M, Hayashi T, Yoshiura K, Hatachi T, Nagayasu T. 2013. A predictive factor of the quality of microarray comparative genomic hybridization analysis for formalin-fixed paraffin-embedded archival tissue. Diagn Mol Pathol 22:174-180.
67. Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, Rapakko K, Nieminen P, Xia B, Pospiech H, Winqvist R. 2013. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 4:2578.
68. Noh JM, Choi DH, Nam SJ, Lee JE, Kim JW, Kim SW, Kang E, Lee MH, Ahn SH, Kim KS, Park SK, Haffty BG. 2012. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients. Breast Cancer Res Treat 131:217-222.
69. Nutting C, Camplejohn RS, Gilchrist R, Tait D, Blake P, Knee G, Yao WQ, Ross G, Fisher C, Eeles R. 2000. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 12:300-304.
70. Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, et al. 2014. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5:5496.
71. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. 2007. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357:2543-2551.
72. Piotrowski A, Bruder CE, Andersson R, Diaz de Stahl T, Menzel U, Sandgren J, Poplawski A, von Tell D, Crasto C, Bogdan A, Bartoszewski R, Bebok Z, et al. 2008. Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat 29:1118-1124.
73. Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, Fu C, Crowley MR, Crossman DK, Armstrong L, Babovic-Vuksanovic D, Bergner A, et al. 2014. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 46:182-187.
74. Qin Y, Choi Y, Zhao H, Simpson JL, Chen ZJ, Rajkovic A. 2007. NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet 81:576-581.
75. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, et al. 2007. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167.
76. Rajasekaran R, Doss GP, Sudandiradoss C, Ramanathan K, Rituraj P, Sethumadhavan R. 2008. Computational and structural investigation of deleterious functional SNPs in breast cancer BRCA2 gene. Sheng Wu Gong Cheng Xue Bao 24:851-856.
77. Rajkovic A, Pangas SA, Ballow D, Suzumori N, Matzuk MM. 2004. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. Science 305:1157-1159.
78. Rennstam K, Ringberg A, Cunliffe HE, Olsson H, Landberg G, Hedenfalk I. 2010. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes Cancer 49:78-90.
79. Rhiem K, Todt U, Wappenschmidt B, Klein A, Wardelmann E, Schmutzler RK. 2010. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res 30:3445-3449.
80. Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SR, Wilkie AO, McVean G, Lunter G. 2014. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet 46:912-918.
81. Ronowicz A, Brzeskwiniewicz M, Madanecki P, Buckley PG, Orlowska E, Renata Ochocka J, Limon J, Piotrowski A. 2012. Regeneration of comparative genomic hybridization oligonucleotide microarrays with dimethylurea. Anal Biochem 426:91-93.
82. Rummel S, Valente AL, Kane JL, Shriver CD, Ellsworth RE. 2012. Genomic (in)stability of the breast tumor microenvironment. Mol Cancer Res 10:1526-1531.
83. Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC. 2012. Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? Breast Cancer Res Treat 136:693-703.
84. Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, Peretz T. 2007. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) 19:490-493.
85. Sambrook J, Russell DW. 2001. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 2344 p. http://www.molecularcloning.com/index.php.
86. Sawyer SL, Tian L, Kahkonen M, Schwartzentruber J, Kircher M, Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, Moilanen JS, Greenberg RA. 2015. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 5:135-142.
87. Shamoo Y. 2003. Structural insights into BRCA2 function. Curr Opin Struct Biol 13:206-211.
88. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomaki K, et al. 2012. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21:5373-5384.
89. Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N, Winship I. 2008. Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer 7:119-124.
90. Spitzer M, Wildenhain J, Rappsilber J, Tyers M. 2014. BoxPlotR: a web tool for generation of box plots. Nat Methods 11:121-122.
91. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, et al. 2007. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39:865-869.
92. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, et al. 2008. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40:703-706.
93. Steffensen AY, Jonson L, Ejlertsen B, Gerdes AM, Nielsen FC, Hansen TV. 2010. Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations. Fam Cancer 9:283-287.
94. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, et al. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-404.
95. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458:719-724.
96. Surowy HM, Sutter C, Mittnacht M, Klaes R, Schaefer D, Evers C, Burgemeister AL, Goehringer C, Dikow N, Heil J, Golatta M, Schott S, et al. 2014. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance. Breast Cancer Res Treat 145:451-460.
97. Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, Fonseca R, Chng WJ. 2014. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 28:2066-2074.
98. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid LM, Couch FJ, Wilson RB, Weber BL. 1997. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 17:444-452.
99. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, et al. 2009. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41:579-584.
100. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, et al. 2010. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42:504-507.
101. Warren M, Lord CJ, Masabanda J, Griffin D, Ashworth A. 2003. Phenotypic effects of heterozygosity for a BRCA2 mutation. Hum Mol Genet 12:2645-2656.
102. Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielser HB, Saxild HH, Nielsen C, Brunak S, Knudsen S. 2002. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 3:research0048.
103. Wu GS. 2004. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3:156-161.
104. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. 2006. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719-729.
105. Yamamoto H, Williams EG, Mouchiroud L, Canto C, Fan W, Downes M, Heligon C, Barish GD, Desvergne B, Evans RM, Schoonjans K, Auwerx J. 2011. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell 147:827-839.
106. Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, Zheng N, Chen PL, Lee WH, Pavletich NP. 2002. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297:1837-1848.
107. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, et al. 2009. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41:324-328.
108. Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, Santoro A, Radice P. 2010. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat 124:251-258.